Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications
Publication partner logo
Publication partner link
https://www.gsk.com

Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.

  • Read more about Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.

Alam, M., Sanchez-Azqueta, A., Janha, O., Flannery, E., Mahindra, A., Mapesa, K., ... Tobin A. (2019). Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682.

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

  • Read more about Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Fong, J., Pignata, L., Goy, P., Kawabata, K., Lee, S., Koh, C., ... Guccione, E. (2019). Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell, 36(2), 194-209.e9.

Gram-scale synthesis of FICZ, a photoreactive endogenous ligand of the aryl hydrocarbon receptor.

  • Read more about Gram-scale synthesis of FICZ, a photoreactive endogenous ligand of the aryl hydrocarbon receptor.

Zhang, C., Creech, K. L., Zuercher, W. J., & Willson, T. M. (2019). Gram-scale synthesis of FICZ, a photoreactive endogenous ligand of the aryl hydrocarbon receptor. Scientific reports, 9(1), 9982.

The promise and peril of chemical probes.

  • Read more about The promise and peril of chemical probes.

Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., … Zuercher, W. J. (2015). The promise and peril of chemical probes. Nature chemical biology, 11(8), 536–541.

Identifying Small Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces.

  • Read more about Identifying Small Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces.

Bowkett, D., Talon, R., Tallant, C., Schofield, C., von Delft, F., Knapp, S., … Brennan, P. E. (2018). Identifying Small-Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces. ChemMedChem, 13(10), 1051–1057.

Synthesis and Demonstration of the Biological Relevance of sp3 -rich Scaffolds Distantly Related to Natural Product Frameworks

  • Read more about Synthesis and Demonstration of the Biological Relevance of sp3 -rich Scaffolds Distantly Related to Natural Product Frameworks

Foley, D. J., Craven, P. G. E., Collins, P. M., Doveston, R. G., Aimon, A., Talon, R., … Nelson, A. (2017). Synthesis and Demonstration of the Biological Relevance of sp3‐rich Scaffolds Distantly Related to Natural Product Frameworks. Chemistry (Weinheim an Der Bergstrasse, Germany), 23(60), 15227–15232.

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10

  • Read more about Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10

Zhang, W., Sartori, M., Makhnevych, T., Federowicz, K., Dong, X., Liu, L., ... Sidhu, S. S. (2017). Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10. Journal Of Molecular Biology, 429(22), 3546-3560.

Assessing histone demethylase inhibitors in cells: lessons learned

  • Read more about Assessing histone demethylase inhibitors in cells: lessons learned

Hatch, S. B., Yapp, C., Montenegro, R. C., Savitsky, P., Gamble, V., Tumber, A., … Müller, S. (2017). Assessing histone demethylase inhibitors in cells: lessons learned. Epigenetics & Chromatin, 10, 9.

Subscribe to GlaxoSmithKline (GSK)
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility